193 related articles for article (PubMed ID: 14747048)
1. Novel approaches to treat asymptomatic, hormone-naive patients with rising prostate-specific antigen after primary treatment for prostate cancer.
Dawson NA; Slovin SF
Urology; 2003 Dec; 62 Suppl 1():102-18. PubMed ID: 14747048
[TBL] [Abstract][Full Text] [Related]
2. A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
Pruthi RS; Derksen JE; Moore D
BJU Int; 2004 Feb; 93(3):275-8. PubMed ID: 14764122
[TBL] [Abstract][Full Text] [Related]
3. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
Berenguer Sánchez A
Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
[No Abstract] [Full Text] [Related]
4. Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), Intergroup/Clinical Trials Support Unit study.
Walczak JR; Carducci MA;
Urology; 2003 Dec; 62 Suppl 1():141-6. PubMed ID: 14747052
[TBL] [Abstract][Full Text] [Related]
5. Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy.
Daskivich TJ; Regan MM; Oh WK
Urology; 2007 Sep; 70(3):527-31. PubMed ID: 17905110
[TBL] [Abstract][Full Text] [Related]
6. Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient.
Gulley J; Dahut WL
Urology; 2003 Dec; 62 Suppl 1():147-54. PubMed ID: 14747053
[TBL] [Abstract][Full Text] [Related]
7. Vaccines as treatment strategies for relapsed prostate cancer: approaches for induction of immunity.
Slovin SF
Hematol Oncol Clin North Am; 2001 Jun; 15(3):477-96. PubMed ID: 11525292
[TBL] [Abstract][Full Text] [Related]
8. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
Sciarra A; Di Silverio F
Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
[TBL] [Abstract][Full Text] [Related]
9. The role of prostate-specific antigen in light of new scientific evidence.
Hernández C; Morote J; Miñana B; Cózar JM
Actas Urol Esp; 2013 Jun; 37(6):324-9. PubMed ID: 23608183
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer.
Loberg RD; Fielhauer JR; Pienta BA; Dresden S; Christmas P; Kalikin LM; Olson KB; Pienta KJ
Urology; 2003 Dec; 62 Suppl 1():128-33. PubMed ID: 14747050
[TBL] [Abstract][Full Text] [Related]
11. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
12. Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer.
Hellerstedt B
Urology; 2003 Dec; 62 Suppl 1():79-86. PubMed ID: 14747045
[TBL] [Abstract][Full Text] [Related]
13. Role of secondary hormonal therapy in the management of recurrent prostate cancer.
Ryan CJ; Small EJ
Urology; 2003 Dec; 62 Suppl 1():87-94. PubMed ID: 14747046
[TBL] [Abstract][Full Text] [Related]
14. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
[TBL] [Abstract][Full Text] [Related]
15. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.
D'Amico AV; Moul JW; Carroll PR; Cote K; Sun L; Lubeck D; Renshaw AA; Loffredo M; Chen MH
J Natl Cancer Inst; 2004 Apr; 96(7):509-15. PubMed ID: 15069112
[TBL] [Abstract][Full Text] [Related]
16. Treatment options in androgen-independent prostate cancer.
Lara PN; Meyers FJ
Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
[TBL] [Abstract][Full Text] [Related]
17. New molecular targets in advanced prostate cancer.
Dawson NA
Expert Rev Anticancer Ther; 2006 Jul; 6(7):993-1002. PubMed ID: 16831072
[TBL] [Abstract][Full Text] [Related]
18. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention.
Basler JW; Piazza GA
J Urol; 2004 Feb; 171(2 Pt 2):S59-62; discussion S62-3. PubMed ID: 14713756
[TBL] [Abstract][Full Text] [Related]
19. Advanced clinical states in prostate cancer.
Cheng HH; Lin DW; Yu EY
Urol Clin North Am; 2012 Nov; 39(4):561-71. PubMed ID: 23084531
[TBL] [Abstract][Full Text] [Related]
20. PSA bounce predicts early success in patients with permanent iodine-125 prostate implant.
Patel C; Elshaikh MA; Angermeier K; Ulchaker J; Klein EA; Chehade N; Wilkinson DA; Reddy CA; Ciezki JP
Urology; 2004 Jan; 63(1):110-3. PubMed ID: 14751360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
